Balyasny Asset Management
BHVN

Balyasny Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Balyasny Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-610,571
Closed -$92.3M – 3586
2022
Q3 		$92.3M Buy
610,571
+276,732
+83% +$41M 0.28% 67
2022
Q2 		$48.6M Buy
+333,839
New +$42.6M 0.16% 153
2021
Q4 		– Sell
-34,446
Closed -$4.79M – 2809
2021
Q3 		$4.79M Buy
+34,446
New +$4.3M 0.02% 839
2021
Q1 		– Sell
-13,627
Closed -$1.17M – 2272
2020
Q4 		$1.17M Buy
+13,627
New +$1.15M 0.01% 990
2019
Q4 		– Sell
-122,231
Closed -$5.1M – 1652
2019
Q3 		$5.1M Buy
122,231
+24,890
+26% +$1.05M 0.04% 542
2019
Q2 		$4.26M Buy
+97,341
New +$5.49M 0.03% 653
2019
Q1 		– Sell
-264,861
Closed -$9.79M – 1824
2018
Q4 		$9.79M Buy
264,861
+257,659
+3,578% +$9.29M 0.07% 361
2018
Q3 		$270K Sell
7,202
-7,005
-49% -$258K ﹤0.01% 1529
2018
Q2 		$561K Buy
+14,207
New +$451K ﹤0.01% 1317

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Balyasny Asset Management's BHVN Position: Q4 2022 in Review

Balyasny Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 610,571 shares — an estimated $92.3M sold.

Balyasny Asset Management first reported a position in BHVN in Q2 2018 and held it in 9 quarters. The position peaked at $92.3M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Balyasny Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 610,571 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $92.3M.
  • Balyasny Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018 and held it in 9 quarters.
  • Balyasny Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $92.3M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.